ArticleThe New England journal of medicine2022
Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults.
Article in The New England journal of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials.Virology journal · 2025Article
- The disappearing COVID-Naïve Population and comparative Roche vs. Abbott Test sensitivity: evidence from antibody seroprevalence in Milwaukee County, Wisconsin.Scientific reports · 2024Article
- Article
- SARS-CoV-2 seroprevalence in Nova Scotia blood donors.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2024Article
- The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study.Frontiers in immunology · 2024Article
- High SARS-CoV-2 seroincidence but low excess COVID mortality in Sierra Leone in 2020-2022.PLOS global public health · 2024Article
- Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.Infectious diseases and therapy · 2023Article
- Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.Nature communications · 2023Article
- PCR Test Positivity and Viral Loads during Three SARS-CoV-2 Viral Waves in Mumbai, India.Biomedicines · 2023Article
- The burden of incidental SARS-CoV-2 infections in hospitalized patients across pandemic waves in Canada.Scientific reports · 2023Article
- Incidence of SARS-CoV-2 Infection Among People Experiencing Homelessness in Toronto, Canada.JAMA network open · 2023Article
- Cross-Canada Variability in Blood Donor SARS-CoV-2 Seroprevalence by Social Determinants of Health.Microbiology spectrum · 2023Article
- Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping.Frontiers in molecular biosciences · 2023Article
- Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose.Frontiers in immunology · 2023Article
- Determining the Longitudinal Serologic Response to COVID-19 Vaccination in the Chronic Kidney Disease Population: A Clinical Research Protocol.Canadian journal of kidney health and disease · 2023Article
- Risk for uveitis relapse after COVID-19 vaccination.Journal of autoimmunity · 2022Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.